These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28028356)

  • 1. Sirtuins and nonalcoholic fatty liver disease.
    Nassir F; Ibdah JA
    World J Gastroenterol; 2016 Dec; 22(46):10084-10092. PubMed ID: 28028356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators.
    Colak Y; Yesil A; Mutlu HH; Caklili OT; Ulasoglu C; Senates E; Takir M; Kostek O; Yilmaz Y; Yilmaz Enc F; Tasan G; Tuncer I
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):311-9. PubMed ID: 25267960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients.
    Wu T; Liu YH; Fu YC; Liu XM; Zhou XH
    Ann Clin Lab Sci; 2014; 44(4):410-8. PubMed ID: 25361925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease.
    Colak Y; Ozturk O; Senates E; Tuncer I; Yorulmaz E; Adali G; Doganay L; Enc FY
    Med Sci Monit; 2011 May; 17(5):HY5-9. PubMed ID: 21525818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging roles of SIRT1 in fatty liver diseases.
    Ding RB; Bao J; Deng CX
    Int J Biol Sci; 2017; 13(7):852-867. PubMed ID: 28808418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clock-NAD
    Aggarwal S; Trehanpati N; Nagarajan P; Ramakrishna G
    J Cell Physiol; 2022 Aug; 237(8):3164-3180. PubMed ID: 35616339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats.
    Deng XQ; Chen LL; Li NX
    Liver Int; 2007 Jun; 27(5):708-15. PubMed ID: 17498258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in Nonalcoholic Fatty Liver Disease: SIRT Family Regulates Mitochondrial Biogenesis.
    Zeng C; Chen M
    Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36008973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic benefits from Sirt1 and Sirt1 activators.
    Chaudhary N; Pfluger PT
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):431-7. PubMed ID: 19474719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirtuins, aging, and metabolism.
    Guarente L
    Cold Spring Harb Symp Quant Biol; 2011; 76():81-90. PubMed ID: 22114328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1.
    Kelly G
    Altern Med Rev; 2010 Sep; 15(3):245-63. PubMed ID: 21155626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuins regulate key aspects of lipid metabolism.
    Lomb DJ; Laurent G; Haigis MC
    Biochim Biophys Acta; 2010 Aug; 1804(8):1652-7. PubMed ID: 19962456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bovine sirtuins: initial characterization and expression of sirtuins 1 and 3 in liver, muscle, and adipose tissue.
    Ghinis-Hozumi Y; González-Gallardo A; González-Dávalos L; Antaramian A; Villarroya F; Shimada A; Varela-Echavarría A; Mora O
    J Anim Sci; 2011 Aug; 89(8):2529-36. PubMed ID: 21421831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirtuins Expression and Their Role in Retinal Diseases.
    Balaiya S; Abu-Amero KK; Kondkar AA; Chalam KV
    Oxid Med Cell Longev; 2017; 2017():3187594. PubMed ID: 28197299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver.
    You M; Liang X; Ajmo JM; Ness GC
    Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G892-8. PubMed ID: 18239056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2.
    Kelly GS
    Altern Med Rev; 2010 Dec; 15(4):313-28. PubMed ID: 21194247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are sirtuins viable targets for improving healthspan and lifespan?
    Baur JA; Ungvari Z; Minor RK; Le Couteur DG; de Cabo R
    Nat Rev Drug Discov; 2012 Jun; 11(6):443-61. PubMed ID: 22653216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT6: therapeutic target for nonalcoholic fatty liver disease.
    Zang M; Gao B
    Trends Endocrinol Metab; 2022 Dec; 33(12):801-803. PubMed ID: 36328906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.
    Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W
    J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.